The drug will launch within a week, it said, with no news yet on pricing, although Biogen did tell Reuters it would be in line with other recently launched ALS treatments and out-of-pocket costs ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of ...

If approved, tofersen would be the first treatment to target a genetic cause of ALS, albeit one ... by 25 January, and Biogen will also have to make the case for its drug at an advisory committee ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $51.6, a high ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...